Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 8/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461757 | 0.87 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL27133026 | 0.87 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL27133027 | 0.87 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL15925285 | 0.87 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL15925288 | 0.87 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5500159 | 0.87 | IL6ST (0.54) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL5495159 | 0.86 | IL6ST (0.47) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL24418522 | 0.86 | IL6ST (0.52) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL13384830 | 0.84 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH | |
| SCHEMBL13378242 | 0.84 | IL6ST (0.49) | IL6STPPARANAAAIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| US-6492562-B1 | INVENTION ALSO RELATES TO NOVEL INTERMEDIATES AND THE RESULTING MODIFIED POLYKETIDES AND ANTIBIOTICS. | KOSAN BIOSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | COASY, KARS1, ACOT7 | IL6ST 1869/4885PPARA 2804/4885NAAA 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.